Company overview
iXCells Biotechnologies provides high-quality primary cells, iPSC-derived cells, custom iPSC services including CRISPR gene editing, and functional bioassay development for drug discovery. Their iPSCore platform integrates iPSC generation, differentiation, and disease modeling to support target validation, screening, and translational studies. Based in San Diego, CA, they serve academic, biotech, and pharma communities with predictive human cellular models.
iXCells Biotechnologies is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include ixcells biotechnologies, ipsc services, primary cells, crispr gene editing, disease modeling.
Structured facts
- Website
- https://ixcellsbiotech.com
- Markets served
- United States & Americas
- Keywords
- ixcells biotechnologies, ipsc services, primary cells, crispr gene editing, disease modeling
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What cell types and services does iXCells offer?
- iXCells offers primary cells, normal and diseased iPSC lines, iPSC-derived cells, custom iPSC services with CRISPR/Cas9 gene editing, differentiation, and functional bioassay development and execution.
- What is iPSCore and its capabilities?
- iPSCore is iXCells' integrated platform combining iPSC generation, genome editing, differentiation, and primary cell isolation for scalable disease modeling, drug screening, and preclinical research.
- Where is iXCells located and what industries do they serve?
- iXCells is headquartered in San Diego, California, founded in 2014, and serves academic, biotech, and pharmaceutical communities with pre-clinical drug discovery solutions focused on disease-relevant cellular models.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
